Lei Lei Wu

The FDA has approved the TROP2-directed ADC Datroway as a first-line option for triple-negative breast cancer, giving Daiichi Sankyo and AstraZeneca a leg up over their competitor Gilead.

Four years after Frank Fan left Legend — a company he co-founded — he's back at ASCO with new CAR-T company Wondercel Therapeutics.

Longtime Allogene CEO David Chang will be stepping down at the end of June. Chang has served as the company's CEO …

Bristol Myers Squibb’s next-gen multiple myeloma drug mezigdomide cut the risk of disease progression or death for certain patients by 52% when added to a treatment regimen.

The NHS-Galleri trial was the first randomized controlled study conducted on a cancer detection blood test, but the findings suggest Grail's tests are not yet be ready for broad and regular cancer screening use, experts not involved with the study said.

When oncologist Brian Wolpin saw the positive results from Revolution Medicines' pivotal pancreatic cancer study for the first time, he was rendered speechless, he told Endpoints News.

As part of a hormone therapy regimen for prostate cancer, J&J’s Erleada cut the risk of metastasis or death by 20% when given around surgery, researchers reported Sunday.

All 18 multiple myeloma patients who have received Kelonia’s in vivo CAR-T therapy thus far have responded to treatment, according to an update shared Sunday.

ASCO: Incyte details Monjuvi’s frontline data in lymphoma; Lilly appears in two plenaries

Legend Biotech's long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.